Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1/PHASE2
5 participants
INTERVENTIONAL
2005-07-31
2010-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Feasibility Study of Cell Therapy in Treatment of Spinal Cord Injury
NCT02237547
Transplantation of Autologous Bone Marrow or Leukapheresis-Derived Stem Cells for Treatment of Spinal Cord Injury
NCT02687672
Autologous Bone Marrow-derived Mononuclear Cells for Acute Spinal Cord Injury
NCT04528550
Autologous Bone Marrow Cell Transplantation in Persons With Acute Spinal Cord Injury- An Indian Pilot Study.
NCT02260713
Subarachnoid Administrations of Adults Autologous Mesenchymal Stromal Cells in SCI
NCT02165904
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Transplantation of bone marrow stromal cell
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Methylprednisolone therapy according to this study can be started within 8 hours after the injury
* Bone marrow stromal cells (BMSCs) incubation can be started within 72 hours after the injury
* Age between 15 and 60
* With the informed consent of obtaining bone marrow and injecting incubated BMSCs.
Exclusion Criteria
* Central spinal cord injury
* Spinal canal stenosis before the injury
* Brain or spinal cord disease before the injury
* Positive serologic test in at least one of the following; HBs antigen, HCV antibody, HIV antibody, or HTLV-1 antibody
* Pregnancy
15 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
OTHER
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kansai Medical University
Moriguchi, Osaka, Japan
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Ohta M, Suzuki Y, Noda T, Ejiri Y, Dezawa M, Kataoka K, Chou H, Ishikawa N, Matsumoto N, Iwashita Y, Mizuta E, Kuno S, Ide C. Bone marrow stromal cells infused into the cerebrospinal fluid promote functional recovery of the injured rat spinal cord with reduced cavity formation. Exp Neurol. 2004 Jun;187(2):266-78. doi: 10.1016/j.expneurol.2004.01.021.
Saito F, Nakatani T, Iwase M, Maeda Y, Murao Y, Suzuki Y, Fukushima M, Ide C. Administration of cultured autologous bone marrow stromal cells into cerebrospinal fluid in spinal injury patients: a pilot study. Restor Neurol Neurosci. 2012;30(2):127-36. doi: 10.3233/RNN-2011-0629.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UHA_SCI0401
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.